You are here

FDA Accepts New Drug Application for Kidney Disease Therapy Tolvaptan

Review set for September (Apr. 12)

The FDA has accepted for priority review a new drug application (NDA) for the potential use of tolvaptan (Otsuka Pharmaceutical Co.) for the treatment of autosomal-dominant polycystic kidney disease (ADPKD). Phase III clinical trial results that form the basis of the regulatory filing were published online in the New England Journal of Medicine.

ADPKD is a hereditary genetic illness characterized by the development of multiple cysts in the kidneys. It is the most common inherited kidney disease and the fourth most common overall cause of kidney failure worldwide. The diagnosed prevalence is estimated to be between 1:1,000 and 1:4,000 globally.

Tolvaptan is a selective V2 vasopressin receptor antagonist that is believed to slow the progression of ADPKD by reducing the development and growth of kidney cysts. These cysts are characteristic of ADPKD and are often associated with pain, hypertension, decreased kidney function, and, ultimately, kidney failure.

The FDA target action date (PDUFA date) for the new NDA is September 1, 2013.

Source: Otsuka; April 12, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time